Optum’s Post

We’re excited to share Optum Rx is the first to develop a new capability that helps address a major provider pain point: prior authorizations. Prior authorization is an important checkpoint helping patients receive coverage for safe, effective care supported by the most up-to-date clinical guidelines. But the process can add manual, time-consuming tasks to providers’ already heavy workloads. Together with our partners, Surescripts and Cleveland Clinic, we developed Optum Rx PreCheck Prior Authorization, an innovative solution that helps automate the prior authorization process for select drugs, including GLP-1s – from 8.5 hours to under 30 seconds. Learn more about Optum’s commitment to providing a better provider and patient experience: http://spr.ly/6044S3QxI

We’re excited to share Optum Rx is the first to develop a new capability that helps address a major provider pain point: prior authorizations. Prior authorization is an important checkpoint helping patients receive coverage for safe, effective care supported by the most up-to-date clinical guidelines. But the process can add manual, time-consuming tasks to providers’ already heavy workloads. Together with our partners, Surescripts and Cleveland Clinic, we developed Optum Rx PreCheck Prior Authorization, an innovative solution that helps automate the prior authorization process for select drugs, including GLP-1s – from 8.5 hours to under 30 seconds. Learn more about Optum’s commitment to providing a better provider and patient experience: http://spr.ly/6042q2Jeq

We’re excited to share Optum Rx is the first to develop a new capability that helps address a major provider pain point: prior authorizations. Prior authorization is an important checkpoint helping patients receive coverage for safe, effective care supported by the most up-to-date clinical guidelines. But the process can add manual, time-consuming tasks to providers’ already heavy workloads. Together with our partners, Surescripts and Cleveland Clinic, we developed Optum Rx PreCheck Prior Authorization, an innovative solution that helps automate the prior authorization process for select drugs, including GLP-1s – from 8.5 hours to under 30 seconds. Learn more about Optum’s commitment to providing a better provider and patient experience: http://spr.ly/6045S4vph

We’re excited to share Optum Rx is the first to develop a new capability that helps address a major provider pain point: prior authorizations. Prior authorization is an important checkpoint helping patients receive coverage for safe, effective care supported by the most up-to-date clinical guidelines. But the process can add manual, time-consuming tasks to providers’ already heavy workloads. Together with our partners, Surescripts and Cleveland Clinic, we developed Optum Rx PreCheck Prior Authorization, an innovative solution that helps automate the prior authorization process for select drugs, including GLP-1s – from 8.5 hours to under 30 seconds. Learn more about Optum’s commitment to providing a better provider and patient experience: http://spr.ly/6047qvF5t

We’re excited to share Optum Rx is the first to develop a new capability that helps address a major provider pain point: prior authorizations. Prior authorization is an important checkpoint helping patients receive coverage for safe, effective care supported by the most up-to-date clinical guidelines. But the process can add manual, time-consuming tasks to providers’ already heavy workloads. Together with our partners, Surescripts and Cleveland Clinic, we developed Optum Rx PreCheck Prior Authorization, an innovative solution that helps automate the prior authorization process for select drugs, including GLP-1s – from 8.5 hours to under 30 seconds. Learn more about Optum’s commitment to providing a better provider and patient experience: http://spr.ly/6043qIU5t #optum #changingHealthCare

Kristina Reeder will be at the #OCTWest conference on Feb. 6-7. Be sure to stop by booth #51 to say hello if you will be attending! Kristina will share insights on how biopharma leaders strategically utilize patient feedback to improve trial outcomes and ultimately enhance patient experiences. For more details about the event, to view our speakers, or to schedule a meeting with Parexel, click here. #PatientsFirst #ClinicalTrials

𝑰𝒕'𝒔 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑻𝒓𝒊𝒂𝒍𝒔 𝑫𝒂𝒚! And what better way to celebrate than to expand trial access to patients and providers. We're excited to announce our Rapid Feasibility Tool, a 100% HIPAA-compliant, easy-to-use tool to understand and showcase your trial site's most valuable asset: your patient population. --- ⛵ To celebrate today's special occasion, we're giving away 3 months of feasibilities — unlimited EMRs, unlimited feasibility reports — if you sign up this week. --- These days, there are countless clinical trial sites with the facilities, equipment, and personnel required to operate most trials. But only 𝙮𝙤𝙪𝙧 site has 𝙮𝙤𝙪𝙧 patient population. We'll help you prove it. Connect the feasibility tool to 1, 10, or 100 EMRs (with aggressive bulk discounts above 3 EMRs) and craft your strongest pitch to sponsors for the trials you really want. Check out the video below! Some FAQs and the link to join the waitlist is in the comments. #clinicaltrialsday #clinicaltrials

I wonder whether sponsors are aware about how challenging patient recruitment is and how risky to choose the wrong site staff to collaborate with. Take a look at the picture bellow, patient recruitment phase drive time and cost of the clinical trials. Do you still choose traditionnel CRO to conduct your trials and identify your sites? Or do you rely on eClinical partners. Post below your solutions

Thinking ahead can save time, money, and lives when it comes to clinical trials and protocols. IRT is often an afterthought in trial planning, but thinking ahead during protocol design can be pivotal in ensuring a safe and effective trial supply. Clinical Supply Leader's Dan Schell recently got a preview of Kelsey Kern's and Irina Grishina's upcoming SCOPE presentation: Case Study: Designing the Right IRT for Direct-to-Patient and Home Treatment Studies. #clinicaltrials #clinicaltrialsupply #SCOPEsummit